{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:44:26Z","timestamp":1785210266790,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To retrospectively analyze real\u2010world treatment patterns in patients with relapsed\/refractory multiple myeloma (RRMM) who initiated third\u2010line treatment in Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>German and Italian administrative claims data were sourced from the German AOK PLUS health insurance fund and Italian local health units (2016\u20132020). Data for the United Kingdom (UK), France, and Spain were sourced from medical chart reviews (MCRs) from 2016 to 2018 (historical) and 2019 to 2021 (new) using electronic case report forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across all countries, immunomodulatory imide drug (IMiD)\u2010based regimens were prominent in the third\u2010line setting. From 2016 to 2020, lenalidomide\u2010dexamethasone was most common in Italy (18.0%) and Germany (12.7%). From 2019 to 2021, the most common regimen was ixazomib\u2010lenalidomide\u2010dexamethasone (67.5%) in the UK, pomalidomide\u2010dexamethasone (17.1%) in France, and daratumumab\u2010bortezomib\u2010dexamethasone (15.0%) in Spain.<\/jats:p>\n                    <jats:p>In the historical data (2016\u20132018), third\u2010line lenalidomide\u2010 and pomalidomide\u2010dexamethasone doublet use across the UK (&gt;47%), France (&gt;46%), and Spain (&gt;33%) was high. From historical to new, triplet use increased in Spain (&gt;19% to &gt;60%) as did anti\u2010CD38 agent use in France (15.1% to 51.9%) and Spain (19.7% to 42.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>From 2016 to 2021, third\u2010line regimens were mostly IMiD based. The MCR data demonstrated evolving treatment choices from 2016 to 2018 and 2019 to 2021, providing insights into uptake of novel agents and current RRMM European clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.14161","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T02:19:42Z","timestamp":1703557182000},"page":"701-713","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world treatment patterns in patients initiating third\u2010line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-1374","authenticated-orcid":false,"given":"Moritz","family":"Lehne","sequence":"first","affiliation":[{"name":"Cytel Inc  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Haematology Oxford University Hospitals, NHS Foundation Trust  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"Universita di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"d'Estrub\u00e9","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Zhuleku","sequence":"additional","affiliation":[{"name":"Cytel Inc  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hanna","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Shukla","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghiani","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmako\u00f6konomie und Arzneimittellogistik e.V.  Wismar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Maywald","sequence":"additional","affiliation":[{"name":"AOK PLUS  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmako\u00f6konomie und Arzneimittellogistik e.V.  Wismar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Kellermann","sequence":"additional","affiliation":[{"name":"TriNetX Oncology GmbH (formerly OncologyInformationService e.K.)  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Perera","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2016.06.150393"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.09.013"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0273-x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2586"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.844779"},{"issue":"4","key":"e_1_2_11_11_1","first-page":"164","article-title":"The management of relapsed and refractory multiple myeloma","volume":"37","author":"Gahvari ZJ","year":"2023","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70282-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13537"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01109-y"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128030"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122706"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1437345"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647636"},{"key":"e_1_2_11_23_1","unstructured":"European Society for Medical Oncology: ESMO management and treatment adapted recommendations in the COVID\u201019 era: multiple myeloma. 2023. Accessed May 30 2023.https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/haematological-malignancies-multiple-myeloma-in-the-covid-19-era"},{"key":"e_1_2_11_24_1","unstructured":"R: A language and environment for statistical computing[computer program].http:\/\/www.R-project.org: R Foundation for Statistical Computing; 2010"},{"key":"e_1_2_11_25_1","unstructured":"National Institute for Health and Care Excellence.Final appraisal document: Lenalidomide plus dexamethasone for previously untreated multiple myeloma. 2019. Accessed October 26 2023.https:\/\/www.nice.org.uk\/guidance\/gid-tag429\/documents\/final-appraisal-determination-document"},{"key":"e_1_2_11_26_1","unstructured":"Electronic Medicines Compendium: DARZALEX Summary of Product Characteristics. Janssen\u2010Cilag Ltd. 2022. Accessed May 30 2023.https:\/\/www.medicines.org.uk\/emc\/product\/7250\/smpc\/"},{"key":"e_1_2_11_27_1","unstructured":"Myeloma UK.News Release. Daratumumab approved for limited use on the NHS in England and Wales. 2018. Accessed June 5 2023.https:\/\/www.myeloma.org.uk\/news\/daratumumab-approved-for-limited-use-on-the-nhs-in-england-and-wales\/"},{"key":"e_1_2_11_28_1","unstructured":"Myeloma UK.News Release. Daratumumab combination treatment approved for NHS use in England and Wales through the Cancer Drugs Fund. 2019. Accessed June 5 2023.https:\/\/www.myeloma.org.uk\/news\/daratumumab-combination-approved-england-wales-cancer-drugs-fund\/"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-02022-z"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04522-y"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2178997"},{"key":"e_1_2_11_32_1","first-page":"466","article-title":"A multinational chart review of real\u2010world treatment patterns and clinical outcomes in patients with relapsed\/refractory multiple myeloma","volume":"52","author":"Kortum KM","year":"2021","journal-title":"HemaSphere"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162693"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.14161","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:58:48Z","timestamp":1772960328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/ejh.14161"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14161","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]},"assertion":[{"value":"2023-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}